Breaking us approves chloroquine for treatment of coronavirus
I think there may be some misinformation here.
The FDA (Food and Drug Administration) has not approved chloroquine for the treatment of COVID-19, also known as coronavirus. In fact, the FDA has issued several warnings and advisories regarding the use of chloroquine and hydroxychloroquine (a related medication) for COVID-19 treatment.
On March 28, 2020, the FDA issued an Emergency Use Authorization (EUA) for chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19, but this was later revoked on June 15, 2020, due to concerns over the medication's safety and efficacy.
The FDA has also issued several warnings about the potential risks associated with using chloroquine and hydroxychloroquine for COVID-19 treatment, including:
- Increased risk of cardiac arrhythmias (abnormal heart rhythms)
- Increased risk of QT prolongation (a condition that can lead to abnormal heart rhythms)
- Increased risk of liver damage
- Increased risk of gastrointestinal side effects
The World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and other reputable health organizations have also not recommended the use of chloroquine or hydroxychloroquine for COVID-19 treatment.
It's important to rely on credible sources of information and consult with healthcare professionals for accurate and evidence-based information on COVID-19 treatment and prevention.